GRI Bio to Present at the 8th Annual IPF Summit
July 01, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Reverse Stock Split
January 26, 2024 08:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 15, 2023 08:05 ET
|
GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...